Welcome to our dedicated page for Vivos Therapeutics SEC filings (Ticker: VVOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking FDA milestones, dentist network expansion, and royalty streams in Vivos Therapeutics filings can feel like navigating medical jargon and legalese at once. Whether you are searching for “Vivos Therapeutics insider trading Form 4 transactions” before earnings or just wondering how the latest 8-K affects competitive positioning, the details are scattered across hundreds of pages.
Stock Titan resolves that pain. Our platform delivers AI-powered summaries that translate dense disclosures into clear insights, then ties every data point back to what moves VVOS shares. Need the “Vivos Therapeutics quarterly earnings report 10-Q filing” distilled into key revenue shifts? Looking for “Vivos Therapeutics annual report 10-K simplified” to see R&D spend or FDA regulatory pathways? We surface it instantly, alongside
- real-time alerts for “Vivos Therapeutics Form 4 insider transactions real-time”
- side-by-side comparisons of each “Vivos Therapeutics proxy statement executive compensation”
- concise breakdowns of “Vivos Therapeutics 8-K material events explained”
Here you will find every form the company submits—10-K, 10-Q, 8-K, S-1, Section 16 filings—plus AI commentary that answers the exact questions professionals ask, like “understanding Vivos Therapeutics SEC documents with AI” or seeking a quick “Vivos Therapeutics earnings report filing analysis.” Monitor “Vivos Therapeutics executive stock transactions Form 4,” follow segment revenue trends, and assess how new clinical data may reshape growth projections, all without wading through technical text. Complex filings, made clear—so you can focus on decision-making, not document hunting.
Vivos Therapeutics, Inc. (VVOS) reported interim financial results reflecting recent acquisition activity and constrained liquidity. The company completed an acquisition (SCN) with total preliminary consideration of about $8.7 million, including $6.0 million cash, 607,287 restricted shares valued at $1.3 million and contingent earn‑out equity estimated at $1.4 million. Goodwill rose to $5.6 million and identifiable intangible assets of $1.9 million were recorded.
For the six months ended June 30, 2025, the company had revenues reported in the periods shown (examples: $3.8 million and $4.1 million in comparative periods shown), operating losses (e.g., $(4.9) million and $(1.9) million in shown periods) and an accumulated deficit of approximately $113.1 million. Cash and cash equivalents were about $4.4 million with total liabilities of approximately $21.5 million, and management disclosed substantial doubt about the company’s ability to continue as a going concern absent additional financing. The company completed financing transactions in 2024–2025 including private placements and PIPE proceeds totaling several million dollars (including $2.7 million received in June 2025 and $3.7 million upon conversion of a bridge note).
Michael C. Skaff filed an initial Form 3 statement of beneficial ownership for Vivos Therapeutics (VVOS), reporting his position as a 10% owner. The filing details significant holdings through two investment vehicles:
Through V-CO Investors LLC:
- 514,498 shares of common stock
- Pre-Funded Warrant for 2,705,768 shares (exercise price: $0.0001, expires 2034)
- Common Stock Purchase Warrant for 3,220,266 shares (exercise price: $2.204, expires 2029)
Through V-Co Investors 2 LLC:
- 828,000 shares of common stock
- Pre-Funded Warrant for 725,258 shares (exercise price: $0.0001, expires 2035)
- Common Stock Purchase Warrant for 2,329,886 shares (exercise price: $2.23, expires 2030)
Skaff serves as Managing Director of SP Manager LLC, which manages both investment vehicles. He disclaims beneficial ownership except for his pecuniary interest.
FAQ
What is the current stock price of Vivos Therapeutics (VVOS)?
What is the market cap of Vivos Therapeutics (VVOS)?
